See relapses that others miss.
Foresight’s peer-reviewed and proprietary PhasED-Seq technology is an ultra-sensitive, liquid-biopsy based test that detects MRD from circulating tumor DNA (ctDNA). PhasED-Seq powers our Foresight CLARITY MRD test and has been validated in thousands of real-world samples from patients with B-cell malignancies, lung cancer, and breast cancer.1,2,3
View PhasED-Seq PublicationsSee levels below 1 part per million
By tracking unique genomic differences between cancer and healthy cells with unparalleled accuracy, Foresight CLARITY can detect ctDNA levels below 1 part per million, which is up to 100 times lower than other methods.